Danielle Valletti, Assistant Editor

AI-enabled scheduling, multidisciplinary coordination, and workflow redesign can help cancer centers manage growing patient volumes without compromising safety or workforce well-being.

The FDA’s expanded approval of lutetium Lu 177 vipivotide tetraxetan introduces PSMA-targeted radioligand therapy to mHSPC.

In the first episode of Pharmacy Focus: Financial Wellness, host Tim Ulbrich, PharmD, introduces the podcast’s mission to help pharmacy professionals manage their finances confidently and build a life aligned with their values.

World Lung Cancer Day presents an opportunity to recognize progress in lung cancer care while emphasizing the persistent need for earlier detection and equitable access to treatment.

Predictive scheduling can improve staffing, pharmacy preparation, infusion capacity, and the overall patient experience.

This roundup highlights 5 key solid tumor updates from July 2026, including new FDA approvals across bladder, breast, and lung cancers, a tissue-agnostic targeted therapy, and a blood-based colorectal cancer screening test.

The phase 2 AZTEC trial found that single- and multifraction SABR, followed by atezolizumab, had similar safety profiles and limited efficacy in advanced TNBC.

Advance verification, multidisciplinary coordination, and AI-enabled forecasting can help infusion centers adjust schedules and treatment plans during chemotherapy shortages.

The FDA approved SimpleScreen CRC, a blood-based screening test for average-risk adults aged 45 and older, potentially expanding screening access.

Adding consolidative thoracic radiotherapy to atezolizumab maintenance increased serious and fatal adverse events without improving survival in patients with ES-SCLC.

This week's episode covers a new AHA scientific statement on caffeine safety and cardiovascular benefit; pharmacist guidance for protecting patients with asthma, COPD, and allergies during wildfire smoke events; and regulatory updates in obstructive sleep apnea and ROS1-positive lung cancer.

Jordan Hill, PharmD, BCOP, discusses the expanded first-line role of sacituzumab govitecan in metastatic triple-negative breast cancer and how PD-L1 status informs its use alone or with pembrolizumab.

Oncology pharmacy teams can integrate newly approved breast cancer therapies into practice while addressing operational barriers, monitoring requirements, and financial toxicity.

Adding palbociclib to anti-HER2 and endocrine maintenance therapy provides a new treatment option for patients with HR-positive, HER2-positive metastatic breast cancer.

Megan May, PharmD, BCOP, FHOPA, FAPO, discusses unanswered questions surrounding antibody-drug conjugate sequencing, biomarker testing, and medication safety in personalized breast cancer care.

Antibody-drug conjugates, evolving HER2 guidelines, and biomarker-driven treatment decisions are transforming breast cancer care and expanding the oncology pharmacist’s role.

A large US registry analysis found that men were more likely than women to be diagnosed with regional or distant disease across 20 nonreproductive cancer sites.

Baseline proton pump inhibitor (PPI) use and, to a lesser extent, antibiotic use were associated with reduced benefit from consolidation durvalumab after chemoradiotherapy in patients with unresectable stage 3 NSCLC.

This week's episode tracks the growing nationwide cyclosporiasis outbreak and its link to lettuce, a new Utah pilot using artificial intelligence to authorize prescription refills, and FDA approvals in Alzheimer disease, precision oncology, and metastatic breast cancer.

Compared with conventional imaging alone, patient-reported outcomes integrated with machine learning may provide an earlier indication of breast cancer recurrence, disease progression, and survival.

Selpercatinib received approval for adults and children 2 years and older with previously treated or treatment-refractory RET fusion–positive solid tumors.

Andrew Li, PharmD, BCOP, discusses key targeted therapy updates in the 2026 ASCO living guideline for stage IV non–small cell lung cancer and how pharmacists can help manage treatment-related toxicities and access barriers.

This week's episode covers a multistate rise in cyclosporiasis infections, insights from a Yale psychiatrist on safety monitoring for psychedelic therapies, and a wave of FDA approvals spanning nephrology, gene therapy, and cell therapy—plus a major expansion of the NIH's All of Us Research Program.

Utah's AI-powered prescription refill pilot is fueling debate over how artificial intelligence can improve medication access and workflow efficiency while preserving the clinical oversight needed to ensure patient safety.

The tool can estimate recurrence risk across multiple subtypes, including those for which no guideline-recommended genomic prognostic tests currently exist.

Researchers found that excess abdominal fat suppresses immune surveillance in the lungs by increasing regulatory T cells, challenging the "obesity paradox."

Danish study links meningioma risk to progestogen contraceptives, including injectable depot medroxyprogesterone acetate and levonorgestrel intrauterine devices.

FDA grants accelerated approval to atacicept-vymj for IgA nephropathy proteinuria, backed by ORIGIN clinical trial results.

Candel Therapeutics has launched the global phase 3 AURORA trial to evaluate investigational viral immunotherapy in patients with advanced non–small cell lung cancer.

A randomized clinical trial found that both family-based therapy and individual psychoeducational motivational therapy improved symptoms of avoidant/restrictive food intake disorder.